* Portage Biotech Inc reported a quarterly adjusted loss of 6 cents per share for the quarter ended in September. The mean expectation of three analysts for the quarter was for a loss of 29 cents per share. * Reported revenue was zero; analysts expected zero. * Portage Biotech Inc's reported EPS for the quarter was a loss of 6 cents. * The mean earnings estimate of analysts had risen by about 2.2% in the last three months. * In the last 30 days there have been no earnings estimate revisions by analysts covering the company. * Portage Biotech Inc shares had fallen by 13.5% this quarter and lost 45.0% so far this year. * The company reported a quarterly loss of $949 thousand. * Wall Street's median 12-month price target for Portage Biotech Inc is $26.00 * The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." This summary was machine generated from Refinitiv data November 29 at 10:04 p.m. All figures in US dollars unless otherwise stated. QUARTER ENDING ESTIMATE ACTUAL BEAT, MET, MISSED Sep. 30 2022 -0.29 -0.06 Beat Jun. 30 2022 -0.30 -0.13 Beat Mar. 31 2022 -0.28 -0.56 Missed Dec. 31 2021 -0.27 -0.26 Beat
